David Chang, M.D., Ph.D, is the President, Chief Executive Officer and Co-Founder of Allogene Therapeutics. He previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of Yescarta® (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma, Blincyto® (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia, IMLYGIC® (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma among others. From 2002 to 2014, he held senior leadership roles at Amgen.

Prior to that, Dr. Chang held faculty appointment in the Department of Medicine and Microbiology, Immunology & Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. in biology from the Massachusetts Institute of Technology and M.D. and Ph.D. from Stanford University. Dr. Chang completed postdoctoral fellowship at MIT and postgraduate clinical training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute at Harvard Medical School.